ABBVIE INC. vs. Acadia Pharmaceuticals Inc.
ABBVIE INC. (ABBV) comes out ahead, leading on 5 of 9 compared factors.
Size & Scale
| ABBV | ACAD | |
|---|---|---|
| Market Cap | $467.12 billion | $3.56 billion |
| Revenue (TTM) | $64.39 billion | $1.14 billion |
| Net Income (TTM) | $6.32 billion | $380.48 million |
ABBV leads on 3 of 3 size & scale factors.
Valuation
| ABBV | ACAD | |
|---|---|---|
| P/E Ratio | 75.22 | 9.27 |
| Price / Book | -79.33 | 2.73 |
| Price / Sales | 7.25 | 3.13 |
ACAD leads on 2 of 3 valuation factors.
Profitability
| ABBV | ACAD | |
|---|---|---|
| Net Margin | 9.81% | 33.42% |
| Return on Equity | -107.29% | 29.12% |
ACAD leads on 2 of 2 profitability factors.
Dividend
| ABBV | ACAD | |
|---|---|---|
| Dividend Yield | 2.60% | — |
| Payout Ratio | 195.48 | — |
ABBV and ACAD split the dividend factors evenly.
Risk & Sentiment
| ABBV | ACAD | |
|---|---|---|
| Short Interest | 0.85% | 5.74% |
ABBV leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABBV overview, ABBV financials, ACAD overview, ACAD financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.